Nexivol

Quick links to important sections

Nexivol

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nexivol

Quick Facts

Property Description
Active ingredient Nebivolol hydrochloride
Form Oral tablet
Pharmacological class Beta-blocker (β-Adrenergic blocking agent)
General purpose Management of high blood pressure (Hypertension)
Origin Synthetic, Racemic mixture

What Type of Medicine is Nexivol (Nebivolol)?

Nexivol is a prescription pharmaceutical preparation whose active ingredient is nebivolol hydrochloride, classified as a β-adrenergic blocking agent, or beta-blocker. This specific medicine belongs to the broader category of antihypertensive agents used to treat elevated blood pressure. The drug exhibits a high degree of cardioselectivity at typical therapeutic doses, minimizing effects on other systems, and is categorized as a modern, third-generation agent.

As an antihypertensive agent, its high-level therapeutic purpose is to assist in the long-term management of high blood pressure (hypertension) in adult patients. Nebivolol functions through a dual mechanism that includes the ability to induce vasodilation in addition to reducing heart rate. This means the drug offers a specialized approach by promoting blood vessel relaxation alongside heart rate modulation.


Composition and Pharmaceutical Form

The drug is supplied for patient use as an oral tablet and is intended solely for oral administration. The active substance, Nebivolol, is a synthetic, single-ingredient product manufactured as a racemic mixture—an equal blend of two forms, d- and l-enantiomers. The overall therapeutic effectiveness, encompassing both the β-1 receptor blockade and the artery-relaxing effect, is fundamentally derived from the fixed and synergistic combination of these two components within the tablet.


The General Purpose: Controlling Blood Pressure

The primary general purpose of Nexivol is to ease the workload on the heart and facilitate blood flow through the circulatory system, which is critical for patients diagnosed with hypertension. This is accomplished because the drug assists in reducing the speed and force of the heart's contractions while simultaneously helping to relax and expand the blood vessel walls. By addressing both the heart’s output and the peripheral vascular resistance, the medicine acts effectively to bring about a necessary reduction in overall blood pressure for hypertensive individuals.

Regulatory References

  1. NIH/MedlinePlus

What side effects are possible with Nexivol?

Possible Side Effects and Safety Information

The safety profile for Nexivol (bempedoic acid) has been established through clinical trials and regulatory review, highlighting specific adverse reactions and safety considerations.

Clinically Significant Adverse Reactions

The most important safety risks documented in regulatory sources are:

  • Hyperuricemia and Gout: Nexivol is associated with an increase in blood uric acid levels (hyperuricemia), which can lead to the development of gout. This elevation generally occurs within the first month of treatment and persists for the duration of therapy. Patients with a prior history of gout have a higher risk of developing gout events.
  • Tendon Rupture: Use of this medication has been associated with an increased risk of tendon rupture or injury, involving tendons such as the rotator cuff, biceps, or Achilles. These events can occur within weeks to months of starting treatment. The risk is elevated in patients over 60 years of age, those with renal failure, those with existing tendon disorders, and those taking corticosteroids or fluoroquinolones.

Other Common Adverse Reactions

The most commonly reported adverse reactions (occurring in ge 2% of patients and more frequently than placebo in clinical trials) include:

  • Upper respiratory tract infection
  • Muscle spasms
  • Back pain
  • Abdominal pain or discomfort
  • Bronchitis
  • Pain in extremity (hands or feet)
  • Anemia (decrease in hemoglobin levels)
  • Elevated liver enzymes

Population-Specific Safety Notes

Nexivol is contraindicated in individuals with a known serious hypersensitivity reaction to the active ingredient. Due to the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment. The manufacturer advises monitoring for signs of hyperuricemia and tendon issues, and discontinuation is required if a tendon rupture is confirmed.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define an overdose of Nexivol (Nebivolol) as an excessive intake that can lead to severe and potentially life-threatening cardiovascular effects. The immediate and primary manifestations are those resulting from excessive beta-adrenergic blockade.

Documented Overdose Manifestations

Clinical Manifestation Severe Outcome
Severe Bradycardia (slow heart rate) Cardiogenic Shock (circulatory failure)
Hypotension (abnormally low blood pressure) Decompensated Cardiac Failure (acute heart failure)
Heart Block (greater than first degree) Difficulty in restarting and maintaining the heartbeat

Required Emergency Action

Immediate medical attention is required upon the recognition of any severe overdose symptom. The official labeling mandates that individuals or caregivers Call the National Poison Control Center immediately upon suspicion of an excessive dose.

Management procedures described in regulatory information are symptomatic and supportive. These procedures include the use of beta-agonists, such as dobutamine or isoproterenol, intended to pharmacologically reverse the beta-blocking effects. For treatment-resistant bradycardia or heart block, Pacemaker insertion may be required. Furthermore, the label advises supportive care such as the intravenous infusion of normal saline and placing the patient in the supine position to manage excessive hypotension.

Therapeutic Uses of Nexivol

What Nexivol Treats: Main Uses and Benefits

Nexivol (Nebivolol) is relevant for easing symptoms related to heightened physiological activity in the cardiovascular system and elevated blood pressure. The primary application is the management of hypertension, and the medication may assist with the management of overall cardiovascular risk.

The medication is commonly applied across therapeutic domains where additional symptomatic support is needed, primarily addressing Chronic High Blood Pressure (Hypertension). It is also considered relevant for easing symptoms related to heightened physiological activity, such as Chronic Heart Failure and stable coronary artery disease. It provides support that generally helps ease the chronic burden on the heart and supports general well-being during symptomatic phases.

Nexivol assists with the management of hypertension in adult patients, including older adults and those with co-existing conditions like Type 2 diabetes. It offers symptomatic relief that helps patients cope more steadily with symptom fluctuations by assisting with management of hypertension.


QuickFact: Relief for Cardiovascular Strain

Domain Conditions Managed Key Symptom Addressed
Cardiovascular Hypertension, Chronic Heart Failure, Stable Coronary Artery Disease Elevated systolic and diastolic blood pressure

Eligibility and Restrictions for Use

Eligibility Scope: Who Can Use Nexivol?

Nexivol is officially approved for use in adult patients (18 years and older) for the management of high blood pressure.

Absolute Contraindications (Do Not Use)

The medicine is strictly contraindicated and prohibited for individuals with:

  • Severe cardiac issues, including severe bradycardia, heart block greater than first degree, cardiogenic shock, or decompensated cardiac failure.
  • Severe hepatic impairment (Child-Pugh Class C).
  • Sick sinus syndrome (unless a permanent pacemaker is installed).
  • Known hypersensitivity to nebivolol or any inactive ingredients.

Restricted and Conditional Use

Specific population groups require caution or are subject to regulatory restrictions:

  • Organ Function: Patients with severe renal impairment or moderate hepatic impairment are restricted to a lower initial starting dose, as defined by the official label.
  • Age: Use in pediatric patients (under 18 years) is not established and not recommended. Elderly patients over 75 years require close monitoring.
  • Pregnancy/Lactation: The medicine must be discontinued as soon as possible upon detection of pregnancy due to documented fetal toxicity risk. Use during lactation is generally not recommended.
  • Comorbidities: Use requires caution in patients with conditions like Peripheral Vascular Disease (PVD), diabetes, or thyrotoxicosis.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for this medicine identifies certain drug classes and substances that may alter its concentration in the body or produce additive effects. This information is based strictly on government regulatory documents.

Interaction Scope

Category Official Regulatory Statement
Medicinal product categories with documented interactions CYP2D6 Inhibitors, Other beta-blockers, Non-dihydropyridine Calcium Channel Blockers, Digitalis Glycosides, Centrally-acting Antihypertensives, NSAIDs, and Antacids.
Mechanistic basis of interactions Inhibition of CYP2D6 leads to increased plasma exposure (pharmacokinetic interaction). Additive negative chronotropic or inotropic effects (pharmacodynamic interaction). Decreased GI absorption (timing-based interaction).
Timing-based interaction rules Administration of antacids must be separated by at least two hours to avoid a documented reduction in nebivolol levels.
Population-specific interaction notes The drug is formally contraindicated in patients with severe hepatic impairment. Interaction risk from CYP2D6 inhibition is noted to be more significant in genetic poor metabolizers.
Interaction-related restrictions Co-administration with aliskiren is contraindicated in patients with diabetes.

Official Interaction Statements

  • Co-administration with strong CYP2D6 inhibitors (e.g., Fluoxetine) is documented to increase the plasma concentration (exposure) of the medicine.
  • The combination with non-dihydropyridine calcium channel blockers (e.g., Verapamil) carries a documented risk of excessive negative chronotropic and inotropic effects.
  • Alcohol consumption is documented to have an additive effect in lowering blood pressure.
  • Concomitant use with NSAIDs may lead to a documented reduction or loss of the antihypertensive effect.

Connection to the Overall Interaction Profile

The regulatory documents define the product’s interaction structure based primarily on two mechanisms: agents that significantly alter drug exposure through the CYP2D6 metabolic pathway and agents that produce an additive pharmacodynamic effect on cardiovascular function. These official statements establish constraints on co-administration, ranging from mandatory timing separation to formal prohibitions, and address specific population and substance interactions.

Mechanism of Action

Nexivol, a substituted benzopyran, functions as a highly selective competitive antagonist at the cardiac beta1-adrenergic receptors. This antagonism prevents the binding of endogenous catecholamines, such as norepinephrine and epinephrine, thereby inhibiting the downstream G-protein coupled cascade. The resultant negative chronotropic and negative inotropic effects lead to a reduction in heart rate and a decrease in myocardial contractility, respectively.

Concurrently, Nexivol possesses a unique secondary mechanism involving the vascular endothelium. Its L-enantiomer acts as an agonist at the beta3-adrenergic receptors, stimulating the activation of endothelial nitric oxide synthase (eNOS). This activation increases the biosynthesis and release of nitric oxide (NO) within the vascular wall. NO, a diffusible gas, induces vascular smooth muscle relaxation by activating guanylate cyclase, which increases the intracellular concentration of cyclic guanosine monophosphate (cGMP). The system-level physiological consequence of the beta1 antagonism and NO-mediated vasodilation is a modulated cardiac output and a reduction in systemic vascular resistance.

Dosage and Administration Information

Nexivol (nebivolol) is administered via the oral route as a tablet and is designated for once-daily use, typically taken at the same time each day. The medicine may be taken with or without food.

For the management of high blood pressure (hypertension), the usual starting dose is 5 mg once daily. Dosing adjustments, if required, are carried out gradually at intervals of 2 weeks or more, with the maximum daily dose established as 40 mg in the U.S. The maximum blood pressure-lowering effect is generally observed within 2 to 4 weeks following a dose change.

For the management of chronic heart failure, treatment is initiated at a lower starting dose of 1.25 mg once daily. This regimen involves a slow upward titration of the dose, doubling the amount at 1–2 week intervals up to a maximum of 10 mg once daily.

Guidelines include specific modifications for certain populations. Patients with severe kidney impairment or moderate liver impairment should start with a lower dose of 2.5 mg once daily. Similarly, an initial dose of 2.5 mg may be considered for older adults (those 65 years and above). A critical procedural instruction is that therapy must not be stopped abruptly; instead, the dose should be gradually reduced over a period of one to two weeks to conclude treatment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nexivol

Evidence for Use in High Blood Pressure (Hypertension)

Research was studied for high blood pressure primarily involving randomized, placebo-controlled trials (RCTs). These short-term studies, conducted during defined time intervals, explored patterns of difference when Nexivol was observed against an inactive pill (placebo) or sometimes against other high blood pressure medications. Research examined outcomes related to systemic imbalance, specifically measuring changes in a patient’s sitting systolic and diastolic blood pressure. The studies was evaluated in adult patients with mild to moderate high blood pressure, including some subgroups of older adults.

Studies reported statistical differences measured in the average blood pressure values between the group taking Nexivol and the group taking the placebo. Research provides insight into short-term changes and contributes to the broader evidence landscape. Long-term effects are not fully established, and there is limited information for long-term outcomes on major cardiovascular events, such as heart attack or stroke, over many years.

Evidence for Use in Chronic Heart Failure

For chronic heart failure, Nexivol was evaluated in a large, dedicated, randomized, placebo-controlled trial, primarily focusing on older adults ge 70 years. This research examined outcomes related to systemic or functional imbalance by monitoring a major combined endpoint: the time until all-cause death or first cardiovascular-related hospital admission. Studies also monitored heart function measurements and tracked patient-reported outcomes describing perceived discomfort.

Findings describe patterns observed in the studies regarding the rates of the combined endpoint when Nexivol was observed in a group compared to the group given placebo. Data for certain groups remain insufficient for younger adults with heart failure, as the main research populations applied only to the populations studied.


What is Still Uncertain About Nexivol Research

While research describes what has been observed so far, there are still areas where certainty remains low and additional study is ongoing. Comparative evidence is lacking against all other treatments in many of the studied populations. This type of research provides context but not individual predictions; findings describe group patterns, not personal outcomes; and research does not determine whether an individual will respond similarly to the group patterns.

Frequently Asked Questions (FAQ)

Common questions about Nexivol (FAQ)

Q: How quickly does Nexivol typically start to show its full effect?

A: Official product information indicates that the level of medicine in the blood reaches its peak concentration within 1.5 to 4 hours after taking a dose. However, the maximum blood pressure-lowering benefit of Nexivol is usually not fully established until 2 to 4 weeks after the start of treatment or after a dose change.


Q: Does Nexivol interact with common over-the-counter pain relievers?

A: Regulatory documents list that the medicine may interact with NSAIDs, which is a drug class that includes several common over-the-counter pain relievers. This interaction may result in a documented reduction or loss of Nexivol's intended effect on blood pressure.


Q: Is Nexivol typically safe for patients with mild kidney problems?

A: Official guidance states that for patients with mild to moderate renal insufficiency, a specific initial dose adjustment is not routinely required. Dosing for these patients may require individualized adjustment. A dose reduction is specifically mandated for severe kidney impairment.


Q: Does Nexivol carry a risk of dependence or withdrawal symptoms if stopped suddenly?

A: Official regulatory documents state that therapy should not be stopped suddenly. Abrupt discontinuation, particularly in patients with underlying heart conditions, is documented to cause severe issues such as a worsening of chest pain (angina) or heart attack. Discontinuation procedures describe the dose being gradually reduced over one to two weeks.


Q: What were the primary efficacy results from the main Phase 3 studies?

A: Research evidence from clinical studies examining high blood pressure showed that the medicine significantly reduced average seated diastolic blood pressure by approximately 3.2–8.3 mmHg. It also demonstrated a reduction in systolic blood pressure ranging from 2.6–11.7 mmHg compared to placebo.


Q: Is Nexivol safe to take with common antidepressants?

A: Official product information notes that certain medications, including some antidepressants (such as Fluoxetine), are strong CYP2D6 inhibitors. Co-administration with these inhibitors may increase the concentration of Nexivol in the blood, potentially requiring increased monitoring.


Q: Does Nexivol's safety profile change with long-term use (over 5 years)?

A: The primary safety profile for the medicine is based on established, shorter-term clinical trials. Regulatory documents indicate that data regarding the long-term effects of Nexivol on major cardiovascular outcomes over many years, as well as specific changes in the side effect profile, are often limited.


Q: What are the signs of an allergic reaction to Nexivol?

A: Official documents describe that signs of a serious allergic reaction (hypersensitivity) may include developing a rash, hives, or itching. More serious signs may involve swelling of the face, lips, tongue, or throat that could cause difficulty breathing.


Q: Is it true that Nexivol can cause significant weight changes?

A: Unusual weight gain or unusual weight loss are both listed as less common side effects in the official safety profile. It is noted that significant weight changes, particularly if related to fluid retention, could also be a sign of worsening heart failure.


Q: Are there any dietary restrictions or foods to avoid while on Nexivol?

A: According to official labeling, the medicine may be taken with or without food. However, the regulatory information specifies that the administration of antacids must be separated by at least two hours from taking Nexivol to ensure proper absorption.


Q: Is there a generic version of Nexivol available for prescription?

A: Yes, the active ingredient in Nexivol, nebivolol hydrochloride, is available in multiple generic oral tablet formulations. This is documented by regulatory bodies that track drug products.


Q: Are there known issues with driving or operating machinery while taking Nexivol?

A: Regulatory safety information states that the medicine may cause effects such as dizziness, light-headedness, or drowsiness in some people. Information indicates that caution may be necessary when driving or operating machinery, especially when first starting the treatment.


Q: Can Nexivol affect a person's sleep patterns?

A: Yes, the official side effect profile lists that insomnia (difficulty sleeping) and nightmares are documented as uncommon adverse reactions to the medicine.


Q: How does the body eliminate Nexivol after it is taken?

A: Official pharmacokinetic studies show that the medicine is extensively processed by the body through metabolism, primarily involving the CYP2D6 enzyme system. It is then eliminated from the body via both the urine and the feces.


Q: What should be done if an occasional dose of Nexivol is missed?

A: Official dosing information suggests that if an occasional dose is missed, the dose is taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the guidelines state the missed dose should be skipped to continue your regular schedule. Taking two doses at once is generally described as being avoided.


Q: Is dizziness a normal temporary side effect when first starting Nexivol?

A: Yes, dizziness and headache are explicitly listed as among the most frequently reported side effects in patients starting the medicine for high blood pressure. These effects are detailed in regulatory adverse reaction sections.


Q: Can Nexivol interfere with the results of certain common lab tests?

A: Regulatory warnings indicate that the medicine may affect your blood sugar levels and may make the symptoms of low blood sugar less obvious in patients with diabetes. Consequently, this may affect the results of blood or urine sugar tests.


Q: What is the expected half-life of Nexivol in the human body?

A: Pharmacokinetic data from the official labeling shows that the active component has an effective half-life of about 12 hours in most individuals (known as extensive metabolizers). This period may extend to around 19 hours in people who metabolize the drug slowly.


Q: Are there any known effects of Nexivol on sexual function?

A: Yes, regulatory safety documents list impotence (erectile dysfunction) as an uncommon side effect of the medicine.


Q: Does Nexivol contain any gluten or common food allergens?

A: Most formulations are documented to contain lactose monohydrate (a type of sugar). Official warnings describe that patients with rare hereditary problems of galactose intolerance are generally advised to avoid this medicine.


Q: Is it considered normal if a person feels more anxious when they begin taking Nexivol?

A: Official regulatory documents list nervousness as a common side effect of the medicine. Anxiety is also explicitly listed as an uncommon adverse reaction.

How should Nexivol be stored and disposed of?

How to Store and Dispose of Nexivol (Nebivolol)

The storage of Nexivol tablets must comply with official labeling to maintain product stability. The medicine must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with permitted excursions to 30 C (86 F). Storage areas must protect the tablets from moisture, excessive heat, direct light, and the medicine must not be frozen.

Required Storage and Safety

  • Keep from Freezing: Do not store the medicine in a freezer.
  • Container: Keep the medicine in a closed container.
  • Child Protection: It is mandatory to keep this medicine out of the reach of children.

Official Disposal Guidelines

Outdated or unused Nexivol tablets should be safely thrown away. Patients are instructed to consult a healthcare professional for guidance on the proper disposal of unused medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nexivol found in:

A-Z Index: